RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround
Rezolute (RZLT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript
Rezolute shares plunge on disappointing Phase 3 congenital hyperinsulinism trial results
Rezolute (NASDAQ:RZLT) shares fell sharply today following the announcement that its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI) did not meet its primary endpoint. The stock fell almost 90% to trade at $1.15 late morning on Thursday.
Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move
Rezolute is positioned for upside with key catalysts ahead, notably the imminent sunRIZE Phase 3 topline readout for Ersodetug. RZLT maintains a solid $152.2M cash position, supporting a ~23-month runway as it advances late-stage programs in rare hyperinsulinism indications. Ersodetug targets both congenital and tumor-associated hyperinsulinism, with promising Phase 2 data and regulatory alignment for streamlined registrational studies.
How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58%
The consensus price target hints at a 56.6% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy
Rezolute (RZLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript
Rezolute, Inc. ( RZLT ) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism November 10, 2025 12:00 PM EST Company Participants Christen Baglaneas Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Brian Roberts - Chief Medical Officer Sunil Karnawat Sunil Karnawat - Chief Commercial Officer Conference Call Participants Mansa Krishnamurthy Azeez Farooki Ry Forseth - Guggenheim Securities, LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Yun Zhong - Wedbush Securities Inc. Presentation Operator Good day, and welcome to the Rezolute Investor Event Conference Call. [Operator instructions].
Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug
Rezolute is advancing ersodetug in two phase 3 trials for hyperinsulinism: sunRIZE for congenital HI and upLIFT for tumor HI, respectively. RZLT secured FDA alignment for the upLIFT pivotal trial, allowing for an open-label design and only needing to recruit 16 patients. Topline data for sunRIZE is expected in December 2025, while upLIFT results are anticipated in the second half of 2026, offering key catalysts for investors to look forward to.
Rezolute: RZ402 Could Be A Surprise Candidate In The Making
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 study using the oral small molecule plasma kallikrein inhibitor RZ402 for the treatment of patients with diabetic macular edema. The global diabetic macular edema market size is projected to reach $7.5 billion by 2034.
